News
TPST
1.000
+29.23%
0.226
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 1d ago
Weekly Report: what happened at TPST last week (0914-0918)?
Weekly Report · 1d ago
Tempest Therapeutics Expands In Vivo CAR-T Collaboration
TipRanks · 5d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 6d ago
Tempest Therapeutics Adjourns Meeting on Governance Changes
TipRanks · 6d ago
Biotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA
NASDAQ · 6d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 6d ago
Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?
Benzinga · 6d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 6d ago
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Benzinga · 6d ago
Tempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's Why
Benzinga · 6d ago
Tempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64%
NASDAQ · 6d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/15 21:06
Tempest Therapeutics Announces New Private Warrant Financing
TipRanks · 09/15 20:32
Tempest Therapeutics enters exclusive option agreement with Hebei Senlang
TipRanks · 09/15 20:10
Weekly Report: what happened at TPST last week (0907-0911)?
Weekly Report · 09/14 10:22
Tempest Announces $2.5 Mln Private Placement, Stock Down
NASDAQ · 09/11 13:32
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 09/11 12:06
More
Webull provides a variety of real-time TPST stock news. You can receive the latest news about Tempest Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.